Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.

Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group.

Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24.

PMID:
28551073
2.

Results from Polish Spondyloarthritis Initiative registry (PolSPI) - methodology and data from - the first year of observation.

Guła Z, Barczyńska T, Brzosko M, Gąsowski J, Jeka S, Jodłowska-Cicio K, Kwaśny-Krochin B, Leszczyński P, Lubiński Ł, Łosińska K, Pawlak-Buś K, Przepiera-Będzak H, Samborski W, Schlabs M, Siedlar M, Sikorska D, Świerkot J, Węgierska M, Wiland P, Korkosz M.

Reumatologia. 2017;55(2):59-64. doi: 10.5114/reum.2017.67599. Epub 2017 Apr 28.

3.

Endothelial dysfunction is independent of inflammation and altered CCR7 T cell expression in patients with ankylosing spondylitis.

Sulicka J, Surdacki A, Korkosz M, Mikołajczyk T, Strach M, Klimek E, Guzik T, Grodzicki T.

Clin Exp Rheumatol. 2017 Apr 18. [Epub ahead of print]

PMID:
28421995
4.

A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, Rubbert-Roth A, Mysler E, Sleeman MA, Godwood A, Sinibaldi D, Guo X, White WI, Wang B, Wu CY, Ryan PC, Close D, Weinblatt ME; EARTH EXPLORER 1 study investigators.

Ann Rheum Dis. 2017 Jun;76(6):1020-1030. doi: 10.1136/annrheumdis-2016-210624. Epub 2017 Feb 17.

5.

Alterations in skin microvascular function in patients with rheumatoid arthritis and ankylosing spondylitis.

Klimek E, Sulicka J, Gryglewska B, Skalska A, Kwaśny-Krochin B, Korkosz M, Grodzicki TK.

Clin Hemorheol Microcirc. 2017;65(1):77-91. doi: 10.3233/CH-15112.

PMID:
27814279
6.

Arterial stiffness is not increased in patients with short duration rheumatoid arthritis and ankylosing spondylitis.

Dzieża-Grudnik A, Sulicka J, Strach M, Siga O, Klimek E, Korkosz M, Grodzicki T.

Blood Press. 2017 Apr;26(2):115-121. doi: 10.1080/08037051.2016.1232586. Epub 2016 Sep 22.

PMID:
27653044
7.

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.

Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group.

Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23.

8.

Polish Medical Society of Radiology and Polish Society of Rheumatology Recommendations for Magnetic Resonance Imaging of Musculoskeletal Disorders in Rheumatology.

Sudoł-Szopińska I, Urbanik A, Wojciechowski W, Warczyńska A, Kapuścińska K, Korkosz M, Jeka S, Kwiatkowska B.

Pol J Radiol. 2015 May 16;80:259-65. doi: 10.12659/PJR.893670. eCollection 2015. Review.

9.

Position of magnetic resonance in the imaging of inflammatory rheumatic diseases.

Korkosz M.

Reumatologia. 2015;53(4):169-70. doi: 10.5114/reum.2015.53993. Epub 2015 Sep 21. No abstract available.

10.

Further international adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire.

Wilburn J, McKenna SP, Twiss J, Rouse M, Korkosz M, Jancovic R, Nemec P, Pacheco-Tena CF, Saraux A, Westhovens R, Durez P, Martin M, Tammaru M.

Rheumatol Int. 2015 Apr;35(4):669-75. doi: 10.1007/s00296-014-3138-4. Epub 2014 Oct 1.

PMID:
25270915
11.

Blood monocyte subsets and selected cardiovascular risk markers in rheumatoid arthritis of short duration in relation to disease activity.

Klimek E, Mikołajczyk T, Sulicka J, Kwaśny-Krochin B, Korkosz M, Osmenda G, Wizner B, Surdacki A, Guzik T, Grodzicki TK, Skalska A.

Biomed Res Int. 2014;2014:736853. doi: 10.1155/2014/736853. Epub 2014 Jul 14.

12.

Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration.

Klimek E, Skalska A, Kwaśny-Krochin B, Surdacki A, Sulicka J, Korkosz M, Fedak D, Kierzkowska I, Wizner B, Grodzicki TK.

Mediators Inflamm. 2014;2014:681635. doi: 10.1155/2014/681635. Epub 2014 Mar 3.

13.

The ratio of anterior and posterior vertebral heights reinforces the utility of DXA in assessment of vertebrae strength.

Tatoń G, Rokita E, Korkosz M, Wróbel A.

Calcif Tissue Int. 2014 Aug;95(2):112-21. doi: 10.1007/s00223-014-9868-1. Epub 2014 May 23.

14.

Yttrium-90 distribution following radiosynoviorthesis of the knee joint in rheumatoid arthritis patients: a SPECT/CT study.

Bielińska A, Korkosz M, Gąsowski J, Tomaszuk M, Staszczak-Sowa A, Kwaśny-Krochin B, Buziak-Bereza M, Hubalewska-Dydejczyk A, Grodzicki T.

Ann Nucl Med. 2014 Aug;28(7):688-92. doi: 10.1007/s12149-014-0827-8. Epub 2014 Mar 5.

15.

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.

Behrens F, Tak PP, Østergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A, Korkosz M, Rekalov D, Zupanets IA, Ejbjerg BJ, Geiseler J, Fresenius J, Korolkiewicz RP, Schottelius AJ, Burkhardt H.

Ann Rheum Dis. 2015 Jun;74(6):1058-64. doi: 10.1136/annrheumdis-2013-204816. Epub 2014 Feb 17.

16.

Blood monocyte heterogeneity and markers of endothelial activation in ankylosing spondylitis.

Surdacki A, Sulicka J, Korkosz M, Mikolajczyk T, Telesinska-Jasiówka D, Klimek E, Kierzkowska I, Guzik T, Grodzicki TK.

J Rheumatol. 2014 Mar;41(3):481-9. doi: 10.3899/jrheum.130803. Epub 2014 Feb 1.

PMID:
24488416
17.

Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.

Korkosz M, Gąsowski J, Leszczyński P, Pawlak-Buś K, Jeka S, Siedlar M, Grodzicki T.

Scand J Rheumatol. 2014;43(1):43-8. doi: 10.3109/03009742.2013.805241. Epub 2013 Sep 8.

PMID:
24447112
18.

Disparate effects of anti-TNF-α therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis.

Korkosz M, Gąsowski J, Surdacki A, Leszczyński P, Pawlak-Buś K, Jeka S, Siedlar M, Grodzicki T.

Pharmacol Rep. 2013;65(4):891-7.

19.

Combining areal DXA bone mineral density and vertebrae postero-anterior width improves the prediction of vertebral strength.

Tatoń G, Rokita E, Wróbel A, Korkosz M.

Skeletal Radiol. 2013 Dec;42(12):1717-25. doi: 10.1007/s00256-013-1723-3. Epub 2013 Oct 1.

20.

High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage.

Korkosz M, Gąsowski J, Leszczyński P, Pawlak-Buś K, Jeka S, Kucharska E, Grodzicki T.

BMC Musculoskelet Disord. 2013 Mar 19;14:99. doi: 10.1186/1471-2474-14-99.

Supplemental Content

Loading ...
Support Center